Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Pharmacogenetics of Antidepressant-Induced Disinhibition

Key facts

Where
Calgary, CanadaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 17 years old?

Source: NCT03953014, who can take part

Where in Canada

  • Child and Adolescent Addiction, Mental Health & PsychiatryCalgary, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Calgary
Trial code
NCT03953014
Record updated
14 May 2026
Original description
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.Read full original descriptionShow less

Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Inclusion: Aged 6 - 24 years; Medical records available; Diagnosis of MDD, anxiety disorder, or OCD; Current or past history of SSRI therapy.

Exclusion: Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder; Inability of parent/legal guardian to give informed consent; Inability of the child to give informed assent; Unwillingness of child to provide saliva sample for genetic analysis.

ClinicalTrials.gov NCT03953014